Immunome(US:IMNM)2025-11-06 21:12Financial Performance - Immunome reported a net loss of $57.5 million for Q3 2025, compared to a net loss of $47.1 million in Q3 2024[10][16]. - The total operating expenses for Q3 2025 were $60.1 million, compared to $53.4 million in Q3 2024[16]. - The accumulated deficit as of September 30, 2025, was $658.3 million, up from $515.8 million at the end of 2024[14]. Cash Position - As of September 30, 2025, cash and cash equivalents totaled $272.6 million, with net proceeds of $44.9 million from equity offerings, expected to fund operations into 2027[10]. - Immunome's total assets increased to $299.4 million as of September 30, 2025, compared to $240.2 million at the end of 2024[14]. Research and Development - Research and development expenses for Q3 2025 were $49.2 million, including stock-based compensation costs of $2.9 million, while general and administrative expenses were $10.9 million, including stock-based compensation of $3.9 million[10]. - The company anticipates topline data for the Phase 3 RINGSIDE trial of varegacestat before the end of 2025, with a potential NDA submission if warranted[2][3]. - Objective responses have been observed in B-cell lymphoma patients treated with IM-1021, with initial data presentation planned for 2026[2][3]. - Immunome received IND clearance for IM-3050 in April 2025 and plans to initiate a Phase 1 study in early 2026[4]. - The company has three preclinical ADCs against solid tumor targets, IM-1617, IM-1340, and IM-1335, advancing towards 2026 IND submissions[5].